OTCMKTS:IPHYF - Innate Pharma News Headlines

$7.02
0.00 (0.00 %)
(As of 06/17/2019 04:00 PM ET)
Today's Range
$7.02
Now: $7.02
$7.02
50-Day Range
$6.39
MA: $6.65
$7.25
52-Week Range
$5.07
Now: $7.02
$10.40
VolumeN/A
Average Volume161 shs
Market Capitalization$404.35 million
P/E Ratio117.00
Dividend YieldN/A
Beta0.03

Headlines

Innate Pharma (OTCMKTS IPHYF) News Headlines

Source:
DateHeadline
INNATE PHARMA: Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICMLINNATE PHARMA: Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICML
www.finanznachrichten.de - June 12 at 1:54 PM
Innate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICMLInnate Pharma to present IPH4102 "TELLOMAK" clinical trial design and preclinical PTCL data at the 2019 ICML
www.marketwatch.com - June 12 at 1:54 PM
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICMLInnate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
finance.yahoo.com - June 12 at 1:54 PM
Innate Pharma announces intention to conduct a registered offering in the United StatesInnate Pharma announces intention to conduct a registered offering in the United States
finance.yahoo.com - June 12 at 1:54 PM
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II studyInnate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
feeds.benzinga.com - June 6 at 4:32 AM
INNATE PHARMA: Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)INNATE PHARMA: Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
www.finanznachrichten.de - May 31 at 10:33 AM
Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
feeds.benzinga.com - May 31 at 2:55 AM
INNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES TARGETING THE ADENOSINE PATHWAY IN "CELL REPORTS"INNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES TARGETING THE ADENOSINE PATHWAY IN "CELL REPORTS"
www.marketwatch.com - May 23 at 10:28 AM
Outcome of Annual General Meeting of May 22, 2019Outcome of Annual General Meeting of May 22, 2019
finance.yahoo.com - May 23 at 10:28 AM
Innate Pharma First Quarter 2019 ReportInnate Pharma First Quarter 2019 Report
feeds.benzinga.com - May 15 at 3:16 AM
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
finance.yahoo.com - May 1 at 10:16 AM
Number of shares and voting rights of Innate Pharma as at April 18, 2019Number of shares and voting rights of Innate Pharma as at April 18, 2019
finance.yahoo.com - April 24 at 10:43 AM
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
finance.yahoo.com - March 20 at 10:09 AM
Innate Pharma: Jennifer Butler appointed as Executive VP, General Manager, USInnate Pharma: Jennifer Butler appointed as Executive VP, General Manager, US
feeds.benzinga.com - March 12 at 4:28 AM
Innate Pharma Poised To Fill A Gap In Cancer ImmunotherapyInnate Pharma Poised To Fill A Gap In Cancer Immunotherapy
seekingalpha.com - February 26 at 11:12 AM
Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive BoardInnate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
finance.yahoo.com - February 12 at 10:57 AM
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SEZARY SYNDROMEINNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SEZARY SYNDROME
www.marketwatch.com - January 29 at 10:27 AM
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROMEINNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME
finance.yahoo.com - January 29 at 10:27 AM
Innate Pharma announces its financial calendar for 2019Innate Pharma announces its financial calendar for 2019
finance.yahoo.com - January 10 at 10:52 AM
INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018
finance.yahoo.com - December 3 at 4:00 PM
INNATE PHARMA : Publication of monalizumab research in the prestigious "Cell" journalINNATE PHARMA : Publication of monalizumab research in the prestigious "Cell" journal
finance.yahoo.com - November 30 at 11:01 AM
INNATE PHARMA : Third quarter 2018 reportINNATE PHARMA : Third quarter 2018 report
finance.yahoo.com - November 15 at 9:51 AM
Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITCInnate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC
feeds.benzinga.com - November 12 at 1:40 AM
INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at November 1, 2018INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at November 1, 2018
finance.yahoo.com - November 8 at 10:07 AM
INNATE PHARMA : clinical data featured as oral presentations at two major upcoming oncology conferencesINNATE PHARMA : clinical data featured as oral presentations at two major upcoming oncology conferences
finance.yahoo.com - November 2 at 10:40 AM
[$$] AstraZeneca Adds Cancer Drugs to Pipeline[$$] AstraZeneca Adds Cancer Drugs to Pipeline
finance.yahoo.com - October 23 at 3:53 PM
TOP NEWS: AstraZeneca Expands Oncology Pact With Innate Pharma (ALLISS)TOP NEWS: AstraZeneca Expands Oncology Pact With Innate Pharma (ALLISS)
www.morningstar.co.uk - October 23 at 10:00 AM
Innate Pharma strengthens and expands its oncology development collaboration with AstraZenecaInnate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
feeds.benzinga.com - October 23 at 2:05 AM
INNATE PHARMA : data presentations on monalizumab at the ESMO annual meeting 2018INNATE PHARMA : data presentations on monalizumab at the ESMO annual meeting 2018
globenewswire.com - October 16 at 9:51 AM
Could Innate Pharma SA’s (EPA:IPH) Investor Composition Impacts Your Returns?Could Innate Pharma SA’s (EPA:IPH) Investor Composition Impacts Your Returns?
finance.yahoo.com - October 16 at 9:51 AM
Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)Innate Pharma reports IPH4102 results in advanced Cutaneous T Cell Lymphoma (CTCL)
feeds.benzinga.com - September 29 at 3:45 AM
Innate Pharma announces data presentations at upcoming scientific meetingsInnate Pharma announces data presentations at upcoming scientific meetings
feeds.benzinga.com - September 10 at 2:31 AM
INNATE PHARMA ANNOUNCES A CHANGE TO ITS 2018 FINANCIAL CALENDARINNATE PHARMA ANNOUNCES A CHANGE TO ITS 2018 FINANCIAL CALENDAR
finance.yahoo.com - August 23 at 10:04 AM
Innate Pharma to participate in the Citi 2018 European Healthcare Conference on June 20, 2018Innate Pharma to participate in the Citi 2018 European Healthcare Conference on June 20, 2018
finance.yahoo.com - June 18 at 12:35 PM
Innate Pharma to present at the Bryan Garnier 3rd Annual Oncology Day on June 13, 2018Innate Pharma to present at the Bryan Garnier 3rd Annual Oncology Day on June 13, 2018
finance.yahoo.com - June 11 at 9:58 AM
INNATE PHARMA : Outcome of Annual General Meeting of May 29, 2018INNATE PHARMA : Outcome of Annual General Meeting of May 29, 2018
finance.yahoo.com - May 30 at 10:16 AM
INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancerINNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer
finance.yahoo.com - May 17 at 10:34 AM
Innate Pharma to hold its AGM on May 29, 2018 and the release of its Reference documentInnate Pharma to hold its AGM on May 29, 2018 and the release of its Reference document
finance.yahoo.com - April 30 at 10:29 AM
Why Innate Pharma SA.’s (EPA:IPH) Investor Composition Impacts Your ReturnsWhy Innate Pharma SA.’s (EPA:IPH) Investor Composition Impacts Your Returns
finance.yahoo.com - April 25 at 3:59 PM
INNATE PHARMA : AACR 2018, New preclinical data further support ongoing programsINNATE PHARMA : AACR 2018, New preclinical data further support ongoing programs
finance.yahoo.com - April 17 at 10:37 AM
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
feeds.benzinga.com - March 15 at 2:49 AM
Innate Pharma Hosts R&D Day Today in LondonInnate Pharma Hosts R&D Day Today in London
finance.yahoo.com - March 8 at 10:54 AM
INNATE PHARMA : Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory BoardINNATE PHARMA : Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board
feeds.benzinga.com - January 31 at 1:08 AM
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JANUARY 1, 2018NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JANUARY 1, 2018
finance.yahoo.com - January 4 at 10:46 AM
Innate Pharma SA : One of the better choices within its peer groupInnate Pharma SA : One of the better choices within its peer group
finance.yahoo.com - December 26 at 11:30 AM
ETFs with exposure to Innate Pharma SA : December 7, 2017ETFs with exposure to Innate Pharma SA : December 7, 2017
finance.yahoo.com - December 7 at 4:19 PM
Innate Pharma SA :IPHYF-US: Earnings Analysis: For the six months ended June 30, 2017 : November 30, 2017Innate Pharma SA :IPHYF-US: Earnings Analysis: For the six months ended June 30, 2017 : November 30, 2017
finance.yahoo.com - November 30 at 11:30 AM
Innate Pharma provides an update on LirilumabInnate Pharma provides an update on Lirilumab
finance.yahoo.com - November 23 at 2:27 AM
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel